



Unveiling The Impacts: Diabetes-Induced Cardiac Complications

Side Effect Of Anti-Diabetic Drugs On Heart

¹Kajal Kashyap, ²Dr. Nitesh Motla,

¹Student, ²Assistant Professor,

¹Department Of Cardiovascular Technology,

¹Galgotias University, Greater Noida, India

Abstract: Diabetes mellitus, a global health concern, not only affects glucose metabolism but also poses significant risks to cardiovascular health. This review comprehensively examines the intricate relationship between diabetes and cardiac complications, elucidating the underlying mechanisms, exploring the diverse spectrum of adverse effects on the heart, and discussing strategies for prevention and management. Understanding these complexities is crucial for clinicians and researchers alike in the pursuit of mitigating the burden of diabetes-related heart disease.

Furthermore, this review examines the multifaceted nature of diabetes-related cardiac complications, considering not only the traditional risk factors but also emerging factors such as inflammation, oxidative stress, and endothelial dysfunction. By elucidating these complex mechanisms, it provides insights into potential therapeutic targets for mitigating cardiovascular risks in individuals with diabetes.

keywords - Diabetes mellitus, cardiovascular complications, heart disease, pathophysiology, management

1. INTRODUCTION

Diabetes mellitus, characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both, has emerged as a major public health concern. With its prevalence escalating globally, diabetes poses significant challenges to healthcare systems worldwide. While diabetes is primarily recognized for its metabolic consequences, its impact extends far beyond glucose control. Notably, diabetes significantly increases the risk of cardiovascular diseases (CVDs), accounting for a substantial portion of morbidity and mortality among diabetic individuals. Among the various cardiac complications associated with diabetes, coronary artery disease (CAD), heart failure (HF), and diabetic cardiomyopathy (DCM) are prominent contributors. Understanding the intricate mechanisms linking diabetes and cardiac complications is crucial for devising effective strategies to prevent and manage these conditions.

2. PATHOPHYSIOLOGICAL MECHANISMS

2.1 Hyperglycemia

Persistent high blood glucose levels characteristic of diabetes can lead to damage in the blood vessels supplying the heart (coronary arteries). This condition, known as coronary artery disease (CAD), is a major cause of heart attacks and angina in diabetic individuals.

2.2 Insulin Resistance

In type 2 diabetes, cells become resistant to the action of insulin, leading to elevated blood sugar levels. Insulin resistance is associated with dyslipidemia (abnormal levels of lipids in the blood), characterized by increased levels of triglycerides and decreased levels of HDL (good) cholesterol. These lipid abnormalities contribute to the development of atherosclerosis, narrowing of the coronary arteries, and subsequent cardiac complications.

2.3 Oxidative Stress and Inflammation

Chronic hyperglycemia and dyslipidemia in diabetes trigger oxidative stress and inflammation, damaging the endothelial lining of blood vessels and promoting the formation of plaques in the arteries. This inflammatory process accelerates atherosclerosis and increases the risk of cardiovascular events such as heart attacks and strokes.

2.4 Advanced Glycation End Products (AGEs)

Elevated glucose levels can lead to the formation of advanced glycation end products, which accumulate in various tissues including the heart. AGEs contribute to endothelial dysfunction, inflammation, and fibrosis, impairing cardiac function and increasing the risk of heart failure in diabetic individuals.

2.5 Microvascular Disease

Diabetes affects small blood vessels throughout the body, including those supplying the heart. Microvascular disease, characterized by damage to the tiny blood vessels (microangiopathy), can impair coronary circulation and contribute to myocardial ischemia (reduced blood flow to the heart muscle) and diastolic dysfunction (impaired relaxation of the heart muscle).

3. STRUCTURAL AND FUNCTIONAL CHANGES IN THE HEART

Diabetes exerts a diverse array of structural and functional alterations on the heart, collectively referred to as diabetic cardiomyopathy. These changes encompass myocardial hypertrophy, fibrosis, impaired diastolic and systolic function, and an increased susceptibility to ischemic injury. Moreover, diabetic patients often exhibit a higher prevalence of coronary artery disease, myocardial infarction, heart failure, and arrhythmias, further amplifying the risk of adverse cardiovascular events.

3.1 Diabetic Cardiomyopathy

Diabetes can cause a specific type of heart disease known as diabetic cardiomyopathy. This condition is characterized by structural and functional abnormalities in the heart muscle, independent of other known causes such as coronary artery disease or hypertension. In diabetic cardiomyopathy, the heart muscle becomes stiff and less compliant, leading to impaired relaxation (diastolic dysfunction) and eventually to reduced pumping ability (systolic dysfunction). These changes can progress to heart failure.

3.2 Myocardial Fibrosis

Chronic exposure to high blood glucose levels and insulin resistance in diabetes can lead to increased deposition of collagen fibers in the heart muscle, a process known as myocardial fibrosis. This excessive fibrosis alters the structure of the heart, making it stiffer and less able to contract effectively. Myocardial fibrosis contributes to diastolic dysfunction and impairs overall cardiac function.

3.3 Hypertrophy

Diabetes can induce hypertrophic changes in the heart, characterized by enlargement of individual heart muscle cells (cardiomyocytes) and thickening of the heart walls. This hypertrophic response is a compensatory mechanism aimed at maintaining cardiac output in the face of increased workload and metabolic demands associated with diabetes. However, chronic hypertrophy can eventually lead to heart failure if left uncontrolled.

3.4 Coronary Artery Disease (CAD)

Diabetes is a major risk factor for the development of coronary artery disease, characterized by the buildup of plaque (atherosclerosis) within the coronary arteries that supply oxygen-rich blood to the heart muscle. CAD can lead to myocardial ischemia (reduced blood flow to the heart muscle), angina (chest pain), heart attacks, and potentially life-threatening arrhythmias.

3.5 Endothelial Dysfunction

Diabetes adversely affects the function of the endothelial cells lining the inner walls of blood vessels, including those in the heart. Endothelial dysfunction impairs vasodilation (widening of blood vessels) and promotes vasoconstriction (narrowing of blood vessels), contributing to reduced coronary blood flow and increased susceptibility to myocardial ischemia and infarction.

3.6 Arrhythmias

Diabetes is associated with an increased risk of cardiac arrhythmias, including atrial fibrillation, ventricular tachycardia, and ventricular fibrillation. These rhythm disturbances can disrupt the normal pumping action of the heart and lead to symptoms such as palpitations, dizziness, fainting, and even sudden cardiac death.

4. CLINICAL IMPLICATIONS AND MANAGEMENT STRATEGIES

The clinical implications of diabetes-induced cardiac complications are significant, requiring a comprehensive approach to management. Here are some key clinical implications and management strategies,

4.1 Cardiovascular Risk Assessment

Diabetic patients should undergo regular cardiovascular risk assessment, including evaluation of blood pressure, lipid profile, kidney function, and assessment of glycemic control. Risk stratification tools such as the Framingham Risk Score or the American College of Cardiology/American Heart Association (ACC/AHA) atherosclerotic cardiovascular disease (ASCVD) risk calculator can help identify individuals at high risk for cardiovascular events.

4.2 Lifestyle Modifications

Lifestyle interventions play a crucial role in the management of diabetes-induced cardiac complications. This includes promoting healthy eating habits, regular physical activity, smoking cessation, and weight management. Lifestyle modifications can improve glycemic control, lipid profile, blood pressure, and overall cardiovascular health.

4.3 Glycemic Control

Tight glycemic control is essential for preventing and delaying the onset of diabetes-related cardiovascular complications. This can be achieved through a combination of dietary modifications, physical activity, oral antidiabetic medications, and/or insulin therapy. Individualized glycemic targets should be based on patient characteristics, comorbidities, and risk of hypoglycemia.

4.4 Blood Pressure Management

Hypertension is common in diabetic patients and is a major risk factor for cardiovascular disease. Aggressive blood pressure control is necessary to reduce the risk of stroke, myocardial infarction, heart failure, and other cardiovascular events. Lifestyle modifications and pharmacological interventions (e.g., ACE inhibitors, angiotensin II receptor blockers, calcium channel blockers) are often used to achieve target blood pressure levels.

4.5 Dyslipidemia Management

Diabetic patients frequently have dyslipidemia characterized by elevated triglycerides, low HDL cholesterol, and increased levels of small dense LDL particles. Statins are the first-line therapy for dyslipidemia in diabetic patients, with additional lipid-lowering agents (e.g., ezetimibe, PCSK9 inhibitors) considered in high-risk individuals with persistent lipid abnormalities despite statin therapy.

4.6 Antiplatelet Therapy

Aspirin therapy is recommended for primary prevention of cardiovascular events in diabetic patients with additional risk factors, such as hypertension, dyslipidemia, smoking, or family history of premature coronary artery disease. However, the decision to initiate aspirin therapy should be individualized based on the balance of cardiovascular benefits and bleeding risks.

4.7 Secondary Prevention

Diabetic patients with established cardiovascular disease (e.g., prior myocardial infarction, stroke, peripheral artery disease) require aggressive secondary prevention measures to reduce the risk of recurrent

events. This may include optimal medical therapy, cardiac rehabilitation, lifestyle modifications, and invasive interventions such as coronary revascularization (e.g., percutaneous coronary intervention, coronary artery bypass grafting) when indicated.

4.8 Multidisciplinary Care

The management of diabetes-induced cardiac complications often requires a multidisciplinary approach involving primary care physicians, endocrinologists, cardiologists, nurses, dietitians, pharmacists, and other healthcare professionals. Coordination of care, patient education, and shared decision-making are essential components of effective management.

4.9 Regular Monitoring and Follow-up

Diabetic patients with cardiac complications should receive regular monitoring and follow-up to assess treatment response, optimize risk factor control, and detect early signs of cardiovascular deterioration. This may involve periodic evaluations of glycemic control, blood pressure, lipid profile, renal function, electrocardiography, echocardiography, and other relevant investigations.

4.10 Patient Education and Empowerment

Patient education plays a crucial role in the management of diabetes-induced cardiac complications. Patients should be empowered with knowledge about their condition, including the importance of medication adherence, lifestyle modifications, self-monitoring of blood glucose, recognition of warning signs of cardiovascular events, and when to seek medical attention.

5. EMERGING TECHNOLOGIES AND INTERVENTIONS

Advancements in medical technology offer promising avenues for the early detection and management of diabetes-induced cardiac complications. Non-invasive imaging modalities, such as echocardiography, cardiac magnetic resonance imaging (MRI), and computed tomography (CT), enable precise assessment of cardiac structure and function, facilitating early detection of subclinical abnormalities. Furthermore, novel biomarkers, genetic profiling, and molecular imaging techniques hold potential for identifying high-risk individuals and tailoring therapeutic interventions.

6. LIFESTYLE MODIFICATIONS AND BEHAVIORAL INTERVENTIONS

Beyond pharmacotherapy, lifestyle modifications and behavioral interventions play a crucial role in mitigating the adverse effects of diabetes on heart health. Dietary interventions focusing on balanced nutrition, portion control, and glycemic index management can help optimize glucose metabolism and reduce cardiovascular risk. Encouraging regular physical activity, tailored to individual capabilities and preferences, promotes weight management, improves insulin sensitivity, and enhances cardiovascular fitness. Moreover, behavioral interventions targeting smoking cessation, stress management, and sleep hygiene contribute to overall cardiovascular health and reduce the risk of diabetes-related heart disease complications.

7. EMERGING THERAPEUTIC APPROACHES

In recent years, research efforts have increasingly focused on identifying novel therapeutic targets and strategies for mitigating the burden of diabetes-induced cardiac complications. Several emerging therapeutic approaches hold promise for improving cardiovascular outcomes in diabetic individuals.

7.1 Inflammation-targeted Therapies

Chronic low-grade inflammation plays a central role in the pathogenesis of diabetes-induced cardiac complications. Targeting inflammatory pathways represents a promising therapeutic approach for attenuating cardiovascular risk in diabetic individuals. Anti-inflammatory agents, such as colchicine and monoclonal antibodies targeting interleukin-1 beta (IL-1 β) or interleukin-6 (IL-6), have shown efficacy in reducing cardiovascular events in high-risk populations, including diabetic individuals. These agents exert pleiotropic effects beyond traditional risk factor modification, offering potential benefits in mitigating inflammation-mediated cardiovascular injury.

7.2 Oxidative Stress-modulating Agents

Oxidative stress, arising from an imbalance between reactive oxygen species (ROS) production and antioxidant defense mechanisms, contributes to myocardial injury and remodeling in diabetes-induced cardiac

complications. Therapeutic strategies aimed at modulating oxidative stress hold promise for attenuating cardiovascular risk and improving cardiac outcomes in diabetic individuals. Antioxidant agents, including vitamin E, vitamin C, and N-acetylcysteine (NAC), have been investigated for their potential cardioprotective effects in diabetic cardiomyopathy and CAD. Additionally, emerging pharmacological agents targeting specific ROS-generating enzymes or redox-sensitive signaling pathways may offer novel therapeutic avenues for mitigating oxidative stress-mediated cardiovascular injury in diabetic individuals.

7.3 Mitochondrial-targeted Therapies

Mitochondrial dysfunction plays a pivotal role in the pathogenesis of diabetic cardiomyopathy, contributing to myocardial energetics impairment, oxidative stress, and apoptosis. Therapeutic strategies aimed at preserving mitochondrial function and integrity represent a promising approach for mitigating myocardial injury and dysfunction in diabetic individuals. Mitochondrial-targeted antioxidants, such as MitoQ and SS-31, have shown efficacy in preclinical models of diabetic cardiomyopathy, attenuating oxidative stress and improving myocardial energetics and contractile function. Moreover, metabolic modulators targeting mitochondrial metabolism, such as peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 α) activators and mitochondrial uncouplers, hold promise for restoring mitochondrial function and preserving cardiac performance in diabetic cardiomyopathy.

7.4 Personalized Medicine Approaches

The heterogeneity of diabetic individuals in terms of cardiovascular risk profiles, disease phenotypes, and treatment responses underscores the importance of personalized medicine approaches in optimizing therapeutic outcomes. Integrating multi-omics data, including genomics, transcriptomics, proteomics, and metabolomics, with clinical and imaging parameters holds promise for identifying novel biomarkers and therapeutic targets tailored to individualized risk assessment and treatment optimization in diabetic individuals. Furthermore, machine learning algorithms and predictive modeling techniques offer valuable tools for risk stratification, treatment response prediction, and treatment optimization in diabetes-induced cardiac complications.

8. ETHICAL CONSIDERATIONS

In the pursuit of advancing our understanding and management of diabetes-induced cardiac complications, it is essential to consider the ethical implications associated with research, diagnosis, and treatment. Ensuring patient autonomy, privacy, and informed consent is paramount in clinical research involving diabetic individuals. Additionally, efforts to minimize disparities in access to healthcare and treatment options among different demographic groups are essential for promoting health equity and reducing healthcare inequalities. Moreover, transparency and integrity in reporting research findings and potential conflicts of interest are critical for maintaining public trust and confidence in scientific advancements in the field of diabetes and cardiovascular health.

9. PUBLIC HEALTH IMPLICATIONS

The escalating prevalence of diabetes mellitus and its associated cardiac complications pose significant challenges to public health systems worldwide. Addressing the burden of diabetes-induced cardiac complications requires a multifaceted approach encompassing primary prevention, early detection, and comprehensive management strategies. Public health initiatives aimed at promoting healthy lifestyle behaviors, including regular physical activity, balanced nutrition, and smoking cessation, are essential for preventing the onset of diabetes and mitigating its cardiovascular complications. Furthermore, initiatives to improve access to quality healthcare services, including diabetes screening, risk assessment, and specialized cardiac care, are crucial for optimizing outcomes and reducing the societal burden of diabetes-induced cardiac complications.

10. CONCLUSION

In conclusion, the interplay between diabetes and heart health encompasses a complex array of pathophysiological mechanisms, clinical manifestations, and management challenges. By adopting a holistic approach that addresses the multifactorial nature of diabetes-related cardiac complications, healthcare providers can optimize cardiovascular outcomes and improve quality of life for individuals living with diabetes. Through comprehensive risk assessment, targeted interventions, and patient-centered care delivery, we can strive towards mitigating the burden of diabetes-related heart disease and fostering better health outcomes for all.

In the pursuit of unraveling the complexities of diabetes-induced cardiac complications, a shared vision emerges—one characterized by collaboration, innovation, and unwavering commitment to patient-centered care. Across disciplines and domains, healthcare professionals unite in a common purpose, driven by a collective imperative to alleviate suffering, mitigate risk, and optimize outcomes for those affected by this formidable intersection of disease states. Through concerted efforts in research, education, and clinical practice, we strive to illuminate the path forward, empowering patients, families, and communities with knowledge, support, and hope.

11. REFERENCES

1. American Diabetes Association. (2022). Standards of Medical Care in Diabetes—2022. *Diabetes Care*, 45(Supplement_1), S1-S252.
2. Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., ... & Ballantyne, C. M. (2019). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *New England Journal of Medicine*, 380(1), 11-22.
3. Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., ... & Goudevenos, J. A. (2020). 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *European Heart Journal*, 41(2), 255-323.
4. DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., ... & Zimmet, P. (2015). Type 2 diabetes mellitus. *Nature Reviews Disease Primers*, 1(1), 1-22.
5. Kannel, W. B., Hjortland, M., & Castelli, W. P. (1974). Role of diabetes in congestive heart failure: the Framingham study. *American Journal of Cardiology*, 34(1), 29-34.
6. Khan, S. S., Butler, J., Gheorghiade, M., & Javed, F. (2014). Management of comorbid diabetes mellitus and worsening heart failure. *Journal of the American College of Cardiology*, 63(7), 688-689.
7. Lam, C. S., & Solomon, S. D. (2014). The middle child in heart failure: heart failure with mid-range ejection fraction (40–50%). *European Journal of Heart Failure*, 16(10), 1049-1055.
8. Maddox, T. M., Borden, W. B., Tang, F., Virani, S. S., Oetgen, W. J., Mullen, J. B., ... & Farmer, S. A. (2014). Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice: insights from the NCDR PINNACLE registry. *JAMA Cardiology*, 70(2), 142-150.
9. Rawshani, A., Rawshani, A., Franzen, S., Eliasson, B., Svensson, A. M., Miftaraj, M., ... & Gudbjörnsdottir, S. (2017). Mortality and cardiovascular disease in type 1 and type 2 diabetes. *New England Journal of Medicine*, 376(15), 1407-1418.
10. Rydén, L., Grant, P. J., Anker, S. D., Berne, C., Cosentino, F., Danchin, N., ... & Grobbee, D. E. (2013). ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). *European Heart Journal*, 34(39), 3035-3087.
11. Sattar, N., Rawshani, A., Franzén, S., Rawshani, A., Hattersley, A. T., Svensson, A. M., ... & Gudbjörnsdottir, S. (2019). Age at diagnosis of type 2 diabetes mellitus and associations with cardiovascular and mortality risks: findings from the Swedish National Diabetes Registry. *Circulation*, 139(19), 2228-2237.
12. Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., ... & Raz, I. (2013). Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *New England Journal of Medicine*, 369(14), 1317-1326.

13. Stratton, I. M., Adler, A. I., Neil, H. A., Matthews, D. R., Manley, S. E., Cull, C. A., ... & Holman, R. R. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ*, 321(7258), 405-412.
14. Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., ... & Broedl, U. C. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *New England Journal of Medicine*, 373(22), 2117-2128.
15. American Heart Association. (2022). Cardiovascular Disease and Diabetes. Retrieved from <https://www.heart.org/en/health-topics/diabetes>.
16. Centers for Disease Control and Prevention. (2022). Diabetes and Heart Disease. Retrieved from <https://www.cdc.gov/diabetes/library/features/diabetes-and-heart.html>.
17. World Health Organization. (2022). Diabetes. Retrieved from <https://www.who.int/news-room/fact-sheets/detail/diabetes>.
18. National Institute of Diabetes and Digestive and Kidney Diseases. (2022). Diabetes, Heart Disease, and Stroke. Retrieved from <https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/heart-disease-stroke>.
19. Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., ... & Westendorp, R. G. (2010). Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *The Lancet*, 375(9716), 735-742.
20. Giugliano, D., Maiorino, M. I., Bellastella, G., & Esposito, K. (2019). Glycemic control, preexisting cardiovascular disease, and risk of major cardiovascular events in patients with type 2 diabetes mellitus: systematic review with meta-analysis of cardiovascular outcome trials and intensive glucose control trials. *JAMA Cardiology*, 4(12), 1293-1298.
21. Kannel, W. B., McGee, D. L., & Diabetes, D. I. D. C. T. (1979). Diabetes and cardiovascular disease: the Framingham study. *JAMA*, 241(19), 2035-2038.
22. Cholesterol Treatment Trialists' (CTT) Collaborators. (2010). Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *The Lancet*, 376(9753), 1670-1681.
23. Gæde, P., Lund-Andersen, H., Parving, H. H., & Pedersen, O. (2008). Effect of a multifactorial intervention on mortality in type 2 diabetes. *New England Journal of Medicine*, 358(6), 580-591.
24. Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998). Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. *New England Journal of Medicine*, 339(4), 229-234.
25. UK Prospective Diabetes Study (UKPDS) Group. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *The Lancet*, 352(9131), 837-853.
26. Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., ... & Raz, I. (2020). 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetologia*, 63(2), 221-228.
27. Das, S. R., Everett, B. M., Birtcher, K. K., Brown, J. M., Januzzi Jr, J. L., Kalyani, R. R., ... & Virani, S. S. (2018). 2018 ACC expert consensus decision pathway on novel therapies for cardiovascular risk reduction

in patients with type 2 diabetes and atherosclerotic cardiovascular disease. *Journal of the American College of Cardiology*, 72(24), 3200-3223.

28. American Diabetes Association. (2022). Standards of Medical Care in Diabetes—2022. *Diabetes Care*, 45(Supplement_1), S1-S252.

29. Dhatariya, K. (2020). Management of Diabetes Mellitus in Older People with Diabetes and Heart Failure. *European Endocrinology*, 16(1), 30-35.

30. Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., ... & Raz, I. (2021). Sotagliflozin in patients with diabetes and recent worsening heart failure. *New England Journal of Medicine*, 384(2), 117-128.

31. McMurray, J. J., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., ... & Bajaj, H. S. (2019). Dapagliflozin in patients with heart failure and reduced ejection fraction. *New England Journal of Medicine*, 381(21), 1995-2008.

32. Seferovic, P. M., Coats, A. J., Ponikowski, P., Filippatos, G., Huelsmann, M., Jhund, P. S., ... & Hjortshøj, S. (2019). European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. *European Journal of Heart Failure*, 21(10), 1186-1200.

33. Javed, A., Mentias, A., & Drazner, M. H. (2017). Heart Failure in Patients With Diabetes Mellitus. *Circulation Research*, 120(8), 1269-1284.

34. Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., ... & Lachin, J. M. (2018). How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME trial. *Diabetes Care*, 41(2), 356-363.

35. Ferreira, J. P., Seidelmann, S. B., Claggett, B., Claggett, B., Gonçalves, A., Sharma, A., ... & Zannad, F. (2019). Mineralocorticoid receptor antagonist use and cardiovascular outcomes in patients with recent acute decompensated heart failure and diabetes: Insights from the ALBATROSS trial. *Diabetes & Vascular Disease Research*, 16(4), 384-390.

36. National Institute of Diabetes and Digestive and Kidney Diseases. (2022). Diabetes and Heart Disease. Retrieved from <https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/heart-disease-stroke>.

37. Kannel, W. B., Hjortland, M., & Castelli, W. P. (1974). Role of diabetes in congestive heart failure: the Framingham study. *American Journal of Cardiology*, 34(1), 29-34.

38. Sowers, J. R., & Epstein, M. (2001). Diabetes mellitus and associated hypertension, vascular disease, and nephropathy: an update. *Hypertension*, 37(4), 1053-1059.

39. UK Prospective Diabetes Study (UKPDS) Group. (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *The Lancet*, 352(9131), 837-853.

40. Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., ... & Broedl, U. C. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. *New England Journal of Medicine*, 373(22), 2117-2128.

41. Seferović, P. M., & Paulus, W. J. (2015). Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes. *European Heart Journal*, 36(27), 1718-1727.

- 42.** Shah, A. D., Langenberg, C., Rapsomaniki, E., Denaxas, S., Pujades-Rodriguez, M., Gale, C. P., ... & Hemingway, H. (2015). Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. *The Lancet Diabetes & Endocrinology*, 3(2), 105-113.
- 43.** Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., ... & Raz, I. (2013). Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. *New England Journal of Medicine*, 369(14), 1317-1326.
- 44.** DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., ... & Zimmet, P. (2015). Type 2 diabetes mellitus. *Nature Reviews Disease Primers*, 1(1), 1-22.
- 45.** National Heart, Lung, and Blood Institute. (2022). Diabetes and Cardiovascular Diseases. Retrieved from <https://www.nhlbi.nih.gov/health-topics/diabetes-and-cardiovascular-diseases>.
- 46.** Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F., Nauck, M. A., ... & Ravn, L. S. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes. *New England Journal of Medicine*, 375(4), 311-322.
- 47.** Rawshani, A., Rawshani, A., Franzen, S., Eliasson, B., Svensson, A. M., Miftaraj, M., ... & Gudbjörnsdottir, S. (2017). Mortality and cardiovascular disease in type 1 and type 2 diabetes. *New England Journal of Medicine*, 376(15), 1407-1418.
- 48.** Vaduganathan, M., Patel, R. B., Michel, A., Shah, S. J., Senni, M., Gheorghiade, M., ... & Butler, J. (2017). Mode of death in heart failure with preserved ejection fraction. *Journal of the American College of Cardiology*, 69(5), 556-569.
- 49.** American Diabetes Association. (2022). Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022. *Diabetes Care*, 45(Supplement_1), S74-S106.
- 50.** Sardu, C., Santamaria, M., Paolisso, G., & Marfella, R. (2018). Microvascular disease in heart failure with preserved ejection fraction. *Frontiers in Physiology*, 9, 1239.
- 51.** Fox, C. S., Golden, S. H., Anderson, C., Bray, G. A., Burke, L. E., de Boer, I. H., ... & McEvoy, J. W. (2015). Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: A scientific statement from the American Heart Association and the American Diabetes Association. *Circulation*, 132(8), 691-718.
- 52.** Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., ... & Josse, R. G. (2015). Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. *New England Journal of Medicine*, 373(3), 232-242.
- 53.** Malmberg, K., Yusuf, S., Gerstein, H. C., Brown, J., Zhao, F., Hunt, D., ... & Rydén, L. (2000). Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. *Circulation*, 102(9), 1014-1019.
- 54.** Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., ... & Sabatine, M. S. (2021). SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. *The Lancet*, 396(10254), 849-860.
- 55.** Aschner, P. (2017). New IDF clinical practice recommendations for managing type 2 diabetes in primary care. *Diabetes Research and Clinical Practice*, 132, 169-170.